Ondine Biomedical (AIM:OBI) told investors that the University of Ottawa Heart Institute recorded a 51.5% reduction in conduit harvest-site surgical site infections after switching from mupirocin to its Steriwave nasal photodisinfection treatment in coronary artery bypass grafting procedures.
The London-listed medical device company, which develops light-activated antimicrobial therapies to prevent hospital-acquired infections, said the findings came from a real-world evaluation of 2,172 CABG procedures at the Heart Institute, described as one of Canada's foremost cardiac centres.
The results were presented at the Canadian Cardiovascular Congress in Ottawa between 15 and 17 October and published in abstract form in the Canadian Journal of Cardiology.
The single-centre analysis compared a 24-month baseline period using mupirocin, covering 1,678 patients, against the first eight months of Steriwave use, covering 494 patients.
Infection rates at the donor incision site, where a vein or artery is harvested to build the bypass graft, fell from 3.3% in the mupirocin era to 1.6% under Steriwave, a reduction Ondine said was statistically significant (p=0.012).
Patient compliance rose to 93.3% under the nurse-led, point-of-care Steriwave protocol, against 35.4% compliance with the multi-day, self-administered mupirocin regimen, and just 17.5% among non-elective patients.
"UOHI's commitment to improving patient outcomes, strengthening antibiotic stewardship, and implementing Steriwave through kindness-based, high-accountability leadership is reflected in the near-universal protocol compliance and encouraging reduction in conduit harvest-site infections," said chief executive Carolyn Cross.
Read more about Ondine Biomedical
- 20/10/26Ondine Biomedical raises £10m as trading resumes on AIM
- 19/10/26Ondine Biomedical launches £10m placing to fund US regulatory push
- 29/04/26Ondine Biomedical raises £5m at 12p to fund NDA preparation
Ondine said the Ottawa findings complement topline results from its 5,188-patient multicentre LANTERN study across 18 North American hospitals, which met its prespecified Bayesian success criterion with a 40.5% relative reduction in 30-day surgical site infections.
The company completed a £10 million placing and subscription on 20 October, issuing 100 million new shares at 10p each, with net proceeds earmarked for commercial expansion, US regulatory activity ahead of a planned mid-2027 New Drug Application, and production and quality systems.
Ondine has said that funding is expected to extend its cash runway into early 2028.